Skip to main content
ChemPartner PharmaTech Co., Ltd. logo

ChemPartner PharmaTech Co., Ltd. — Investor Relations & Filings

Ticker · 300149 ISIN · CNE100000Y27 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 2,256 across all filing types
Latest filing 2017-06-16 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300149

About ChemPartner PharmaTech Co., Ltd.

https://www.chempartner.com

ChemPartner PharmaTech Co., Ltd. is a global research and development organization providing comprehensive drug discovery and development services. Operating as a Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO), the company supports pharmaceutical and biotechnology clients through an integrated service platform. Core capabilities include medicinal chemistry, biology, pharmacology, drug metabolism and pharmacokinetics (DMPK), and toxicology. The organization also offers specialized expertise in biologics discovery, protein engineering, and antibody development. ChemPartner facilitates the transition from early-stage research to clinical development through its pharmaceutical development and manufacturing capabilities, utilizing advanced technology to accelerate the discovery and production of novel therapeutic agents.

Recent filings

Filing Released Lang Actions
第三届董事会第二十九次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Quantum Hi-Tech (China) Biological Co., Ltd. It details decisions on share transfer, use of funds for investment, and related party transactions. The text includes voting results and authorization for the chairman to sign agreements. There is no financial data or report content, but rather a summary of board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2017-06-16 Chinese
关于2017年第二次临时股东大会增加临时提案暨股东大会补充通知的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2017 second extraordinary general meeting of shareholders for Quantum Hi-Tech (China) Biological Co., Ltd. It includes information about the meeting date, location, agenda items, voting procedures, and proxy forms. The content focuses on notifying shareholders about the meeting and the proposals to be voted on, including a stock option incentive plan and use of funds. There are no financial statements or management discussion and analysis present. The document is longer than 5,000 characters and contains detailed meeting and voting information, which aligns with a Proxy Solicitation & Information Statement rather than a simple announcement or voting results. Therefore, the document fits best under the category of Proxy Solicitation & Information Statement (PSI).
2017-06-16 Chinese
独立董事关于第三届董事会第二十九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the 29th meeting of the third board of directors of Quantum Hi-Tech (China) Biological Co., Ltd. It references compliance with stock exchange listing rules and company internal regulations, and provides independent opinions on the use of excess raised funds and related party transactions. The document is a formal opinion letter from independent directors rather than a full financial report, earnings release, or regulatory filing. It does not contain financial statements or detailed financial data. It is not an announcement of voting results or a management change. Given the nature of the document as an independent directors' opinion on board meeting matters, it fits best under Board/Management Information (MANG). The document length is short (1021 characters), and it is not a report publication announcement or certification letter. Therefore, the classification is MANG with high confidence.
2017-06-16 Chinese
关于召开2017年第二次临时股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about convening the 2017 second extraordinary general meeting of shareholders for Quantum Hi-Tech (China) Biological Co., Ltd. It includes information about the meeting date, voting procedures (including online voting), agenda items related to a stock option incentive plan, registration procedures, and attachments such as proxy forms and shareholder registration forms. There is no financial data or report content; rather, it is an announcement and procedural notice for a shareholders meeting. This fits the category of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting or similar shareholder meetings. The document length is over 5,000 characters and contains detailed meeting information, not just a brief announcement, so it is not a Report Publication Announcement (RPA). Therefore, the correct classification is AGM Information (AGM-R).
2017-06-12 Chinese
2017年股票期权激励计划（草案）摘要
Capital/Financing Update Classification · 95% confidence The document is a detailed summary of a 2017 stock option incentive plan (草案) for Quantum Hi-Tech (China) Biological Co., Ltd. It includes legal references, plan purpose, management structure, eligibility, stock option quantities, pricing, vesting conditions, accounting treatment, and handling of changes. It is a comprehensive plan document related to stock-based compensation and incentive arrangements for company executives and key personnel. It is not an announcement of a report, nor a financial statement or earnings release. It is not a regulatory filing or certification. It is a detailed plan document related to capital structure and financing activities, specifically a stock option incentive plan involving issuance of shares to employees. Therefore, the best fitting category is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2017-06-12 Chinese
关于提供资料真实、准确、完整的承诺函（二）
Regulatory Filings Classification · 95% confidence The document is a commitment letter from the company's directors, supervisors, and senior management regarding the accuracy and completeness of information provided for a transaction involving the acquisition of a company and related fundraising. It contains declarations and legal commitments but does not include financial data, audit results, or detailed report content. It is not a financial report, earnings release, or management discussion. It is also not a regulatory announcement of voting results or a proxy statement. The document is a legal commitment related to a transaction but does not fit the M&A Activity (TAR) category as it is not an announcement or filing of the transaction itself. Given the nature of the document as a legal attestation and commitment letter, it best fits under Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2017-06-12 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.